A multi‑center retrospective analysis of the effect of DPP4 inhibitors on progression‑free survival in advanced airway and colorectal cancers

  • Authors:
    • Azka Ali
    • Alejandra Fuentes
    • William Paul Skelton Iv
    • Yu Wang
    • Susan McGorray
    • Chintan Shah
    • Rohit Bishnoi
    • Long H. Dang
    • Nam H. Dang
  • View Affiliations

  • Published online on: November 13, 2018     https://doi.org/10.3892/mco.2018.1766
  • Pages: 118-124
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cluster of differentiation 26 (CD26), also known as dipeptidyl peptidase IV (DPP4), is a cell surface protein with exopeptidase activity and is expressed by most cell types. CD26/DPP4 is a multifunctional molecule with diverse biological effects, including regulatory effects on tumor growth, invasion and metastasis, and is a potential novel therapeutic target for selected cancers. In this study, we retrospectively analyzed diabetic patients with concurrent advanced airway or colorectal cancer to examine the effect of DPP4‑inhibitors on progression‑free survival (PFS). We performed a multi‑center retrospective review of patients with advanced colorectal or airway (lung, head and neck) cancer and a concurrent diagnosis of diabetes. The control group included patients on metformin and a sulfonylurea, and the study group included patients on metformin and a DPP4 inhibitor. Ninety‑six patients were eligible for the study. The cancers progressed in 23.7% of patients treated with DPP4 inhibitors compared to 50.9% of patients in the control group with an odds ratio of 0.303 [95% confidence interval (CI): 0.106‑0.809] and P=0.010. There was a statistically significant improvement in PFS in the study group as compared to the control group, hazard ratio=0.42 (95% CI: 0.21‑0.84) and P=0.014. There was a trend toward improvement in overall survival, although this effect was not statistically significant (P=0.11). Exposure to DPP4 inhibitors in the study group led to higher PFS in patients with advanced colorectal and airway cancers. Additional investigations with larger patient cohorts are needed to validate the relationship between DPP4 inhibition and the clinical outcome of selected malignancies.
View Figures
View References

Related Articles

Journal Cover

January 2019
Volume 10 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ali, A., Fuentes, A., Skelton Iv, W.P., Wang, Y., McGorray, S., Shah, C. ... Dang, N.H. (2019). A multi‑center retrospective analysis of the effect of DPP4 inhibitors on progression‑free survival in advanced airway and colorectal cancers. Molecular and Clinical Oncology, 10, 118-124. https://doi.org/10.3892/mco.2018.1766
MLA
Ali, A., Fuentes, A., Skelton Iv, W. P., Wang, Y., McGorray, S., Shah, C., Bishnoi, R., Dang, L. H., Dang, N. H."A multi‑center retrospective analysis of the effect of DPP4 inhibitors on progression‑free survival in advanced airway and colorectal cancers". Molecular and Clinical Oncology 10.1 (2019): 118-124.
Chicago
Ali, A., Fuentes, A., Skelton Iv, W. P., Wang, Y., McGorray, S., Shah, C., Bishnoi, R., Dang, L. H., Dang, N. H."A multi‑center retrospective analysis of the effect of DPP4 inhibitors on progression‑free survival in advanced airway and colorectal cancers". Molecular and Clinical Oncology 10, no. 1 (2019): 118-124. https://doi.org/10.3892/mco.2018.1766